You are here: Industry Insights > BMS

News List

Array BioPharma and Bristol-Myers Squibb announce strategic collaboration worldpharmanews
June 01, 2017
Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety...
Array, BMS in Opdivo Clinical Combo Alliance contractpharma
May 31, 2017
To investigate Array's binimetinib in combination with BMS' Opdivo and Opdivo + Yervoy regimen in colorectal cancer
FDA accepts for priority review BMS’s application for Opdivo in previously treated hepatocellular ca cphi-online
May 31, 2017
Application is based on results from the Phase I/II CheckMate -040 trial.
EMA validates application for BMS’s Sprycel in children with chronic myelogenous leukemia cphi-online
May 25, 2017
Proposal extends application to the treatment of children and adolescents with chronic phase Philadelphia-chromosome positive chronic myelogenous leukemia and to the powder for oral suspension.
Is Pfizer to buy BMS? CEO Read hinted at the possibility en-cphi.cn
May 12, 2017
Is the industry giant Pfizer planning to make another acquisition?
Bavarian Nordic, BMS kick off phase 2 testing Prostvac with Opdivo, Yervoy in presurgery prostate ca fiercepharma
April 26, 2017
In a new phase 2 trial, Bavarian Nordic and Bristol-Myers Squibb plan to test the power of the Big Pharma's immunotherapies when paired up with the vaccine maker's prostate-cancer fighter Prostvac.
BMS-986036 shows consistent improvement in liver fat, liver injury and fibrosis in patients with NAS cphi-online
April 25, 2017
Primary endpoint of significant reduction in liver fat achieved following 16 weeks of treatment with BMS-986036.
BMS presents promising data for NASH drug pharmatimes
April 25, 2017
Bristol-Myers Squibb’s investigational liver disease candidate has hit its targets in a mid-stage trial, supporting further research...
BMS Phase II study in non-alcoholic steatohepatitis a success europeanpharmaceuticalreview
April 25, 2017
BMS-986036 is a pegylated analogue of human fibroblast growth factor 21, a key regulator of metabolism. In preclinical models of non-alcoholic steatohepatitis (NASH), BMS-986036 improved steatosis, inflammation, hepatocyte ballooning, and fibrosis.
Bristol-Myers Squibb and Nordic Bioscience Announce Collaboration for Fibrosis Biomarker Technology americanpharmaceuticalreview
April 20, 2017
Bristol-Myers Squibb Company and Nordic Bioscience have announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis (NASH).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page